§ Claim under review · Study
"A systematic review and meta-analysis published in the Journal of Obstetrics and
Verdict
Mostly accurate
Confidence
HighSummary
This citation is real and accurately reported. The 2022 meta-analysis in the Journal of Obstetrics and Gynaecology Research does exist, PMID 35266254 is correct, and it did find a statistically significant reduction in overall PMS severity with omega-3 supplementation across eight randomized trials involving about 676 women. The summary is honest about the study's weaknesses, correctly noting the very high variability between trials and the authors' own call for more research. Two things are worth adding. The benefit for psychological symptoms was less than half the size of the benefit for physical symptoms and only barely reached statistical significance, so presenting the two as equivalent overstates the mood side. Also, one of the eight included trials was retracted in 2023, after this meta-analysis was published, which weakens the evidence base in a way no reader of the original abstract would know. The specific symptoms mentioned, bloating, breast tenderness, mood swings and irritability, were not analyzed as separate pooled outcomes and appear to have been added as examples.
The readings
key figures from the evidenceomega-3 effect on overall PMS severity
omega-3 effect on somatic PMS symptoms
omega-3 effect on psychological PMS symptoms
Why this verdict
Evidence
The citation is real and correctly attributed. Mohammadi, Dehghan Nayeri, Mashhadi and Varaei (2022), J. Obstet. Gynaecol. Res., 48: 1293-1305, doi 10.1111/jog.15217 , PMID 35266254.
The reported findings match the abstract closely. The meta-analysis found omega-3 fatty acids efficient in reducing PMS severity (SMD = -0.968, 95% CI -1.471 to -0.464), with heterogeneous studies (I2 = 89.11%, p <0.001) . Meta-regression showed that aging (β = -0.150, 95% CI -0.202 to -0.098, p <0.001) and increasing duration of intervention (β = -0.579, 95% CI -0.781 to -0.378, p <0.001) had a significant effect on PMS severity . The authors also found omega-3 could significantly reduce somatic (SMD = -0.800, 95% CI -1.126 to -0.474) and psychological (SMD = -0.373, 95% CI -0.686 to -0.061) symptoms of PMS .
The authors' own stated caution matches the claim's final paragraph. Omega-3 fatty acids could reduce PMS severity; however, the authors stated caution is needed in affirming beneficial effects since heterogeneity is evident in the analysis, and that treatment efficacy was enhanced by increased treatment duration .
Findings
✓ What's accurate 7
- The journal, year, authors and PMID are all correct. The paper is real and correctly cited.
- "Significantly reduced the overall severity of PMS" is accurate: SMD -0.968, CI excludes zero.
- "Analyzed randomized clinical trials" is accurate.
- Both symptom domains did reach statistical significance separately, as somatic and psychological subgroups.
- "Longer treatment durations were associated with greater improvements" is accurate and is stated in the abstract itself.
- "Considerable variability" is accurate and understates nothing: I2 of 89.11% is very high heterogeneity, and the authors explicitly flagged it as a reason for caution.
- "Additional high-quality research is needed" is consistent with the authors' stated caution.
≈ What's misleading 5
- Omitted qualifier (magnitude asymmetry): the claim presents physical and psychological benefits as parallel and equivalent. In the source, the psychological effect (SMD -0.373) is less than half the somatic effect (SMD -0.800), and its confidence interval extends to -0.061, meaning the psychological benefit is small and only marginally distinguishable from no effect. A reader of the claim would not know this.
- Added specificity not in the pooled analysis: the source reports composite "somatic" and "psychological" domains. It does not report pooled results for bloating, breast tenderness, mood swings, or irritability as individual outcomes. Those four examples appear to be illustrative additions by whoever wrote the summary. Individual symptoms like bloating and breast tenderness were reported in individual included trials, including the now-retracted one, but attributing them to the meta-analysis overstates its granularity.
- Omitted qualifier (retraction): the claim presents the evidence base as intact. One of the eight included trials has been retracted.
- Temporal overreach, mild: "consistent omega-3 supplementation may provide increasing benefits over time" is an interpretive extension. The underlying finding is a meta-regression across eight trials of differing designs, which is observational at the study level and cannot establish that a given individual accrues increasing benefit. The claim's hedges ("associated with," "may") keep this within bounds, but the inference is exploratory rather than demonstrated.
- Omitted context: the same meta-regression found age significantly associated with PMS severity, indicating the duration effect is entangled with other study-level differences.
? What's uncertain 4
- Full-text detail could not be retrieved: the specific risk-of-bias ratings for each of the eight trials, the individual dose and formulation ranges, and the trial-level duration values are not available from the abstract alone.
- Whether the pooled estimate would remain statistically significant after removing the retracted Sohrabi trial cannot be determined without the full data table.
- The reason for the Sohrabi retraction was not retrieved, so its severity is unknown.
- An SMD of -0.968 is a very large effect for a nutritional intervention. Whether this reflects genuine efficacy or small-study and publication bias cannot be resolved from the abstract, though the 89% heterogeneity is consistent with the latter concern.
Sources
Mohammadi MM, Dehghan Nayeri N, Mashhadi M, Varaei S. "Effect of omega-3 fatty acids on
Retraction notice: Sohrabi N, et al. Complement Ther Med. 2023;72:102919 (retracting the 2013
Later citing reviews characterizing the evidence base (Nutrients 2024; ScienceDirect 2025